Drug Profile
CC 90006
Alternative Names: Anti-PD-1 Agonist - AnaptysBio; C-90006; CC-90006; PD-1 agonist antibody - AnaptysBio/Celgene CorporationLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator AnaptysBio
- Developer Celgene Corporation
- Class Antibodies; Antipsoriatics
- Mechanism of Action Programmed cell death 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Psoriasis
- No development reported Autoimmune disorders
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for phase-I development in Psoriasis in USA (SC)
- 10 Mar 2021 CC 90006 is still in phase I trials for Psoriasis in USA and Canada (SC) (AnaptysBio pipeline, March 2021)
- 28 Feb 2021 No recent reports of development identified for phase-I development in Psoriasis in Canada (SC)